Abstract
Induced pluripotent stem cells (iPSCs) represent an invaluable tool in a chromosomal instability syndrome such as Fanconi anemia (FA), as they can allow to study of the molecular defects underlying this disease. Many other applications, such as its use as a platform to test different methods or compounds, could also be of interest. But the greatest impact of iPSCs may be in bone marrow failure diseases, as iPSCs could represent an unlimited source of autologous cells to apply in advanced treatments such as gene therapy. At the same time, genome editing constitutes the next generation of technology to further develop a safer, personalized, targeted gene therapy. Despite the promising advantages that these two technologies would present in a disease such as FA, the specific characteristics of the disease make both of these processes especially challenging. Efficient and safer FA-hiPSC (human induced pluripotent stem cell) generation methods, robust and reliable differentiation protocols for iPSCs, as well as really efficient delivery methods to perform targeted gene correction should be developed.
Keywords: Induced pluripotent stem cells, Gene editing, Fanconi anemia, Gene therapy.
Current Gene Therapy
Title:Induced Pluripotency and Gene Editing in Fanconi Anemia
Volume: 16 Issue: 5
Author(s): Susana Navarro, Alessandra Giorgetti, Angel Raya and Jakub Tolar
Affiliation:
Keywords: Induced pluripotent stem cells, Gene editing, Fanconi anemia, Gene therapy.
Abstract: Induced pluripotent stem cells (iPSCs) represent an invaluable tool in a chromosomal instability syndrome such as Fanconi anemia (FA), as they can allow to study of the molecular defects underlying this disease. Many other applications, such as its use as a platform to test different methods or compounds, could also be of interest. But the greatest impact of iPSCs may be in bone marrow failure diseases, as iPSCs could represent an unlimited source of autologous cells to apply in advanced treatments such as gene therapy. At the same time, genome editing constitutes the next generation of technology to further develop a safer, personalized, targeted gene therapy. Despite the promising advantages that these two technologies would present in a disease such as FA, the specific characteristics of the disease make both of these processes especially challenging. Efficient and safer FA-hiPSC (human induced pluripotent stem cell) generation methods, robust and reliable differentiation protocols for iPSCs, as well as really efficient delivery methods to perform targeted gene correction should be developed.
Export Options
About this article
Cite this article as:
Navarro Susana, Giorgetti Alessandra, Raya Angel and Tolar Jakub, Induced Pluripotency and Gene Editing in Fanconi Anemia, Current Gene Therapy 2016; 16 (5) . https://dx.doi.org/10.2174/1566523217666170118112050
DOI https://dx.doi.org/10.2174/1566523217666170118112050 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Systematic Analysis of the Expression Profile and Prognostic Significance
of the IGF2BP Family in Lung Adenocarcinoma
Current Cancer Drug Targets The Role of Chronic Periodontitis in Prevention and Treatment of Head and Neck Cancers
Current Cancer Therapy Reviews Hypocholesterolemia
Current Vascular Pharmacology Pin1: A New Genetic Link between Alzheimer’s Disease, Cancer and Aging
Current Aging Science Esophagitis, Treatment-Related Toxicity in Non-Small Cell Lung Cancer
Reviews on Recent Clinical Trials Targeting of Adhesion Molecules as a Therapeutic Strategy in Multiple Myeloma
Current Cancer Drug Targets Novel Metals and Metal Complexes as Platforms for Cancer Therapy
Current Pharmaceutical Design Cancer Drug Development Using Glucose Metabolism Radiopharmaceuticals
Current Pharmaceutical Design Targeting Cancer: The Challenges and Successes of Structure-Based Drug Design Against the Human Purinome
Current Topics in Medicinal Chemistry Biological Activity of Carotenoids: Its Implications in Cancer Risk and Prevention
Current Pharmaceutical Biotechnology Optimizing Tumor-Reactive γδT Cells for Antibody-Based Cancer Immunotherapy
Current Molecular Medicine Innovative Strategies in In Vivo Apoptosis Imaging
Current Medicinal Chemistry Sentinel Node Imaging
Current Medical Imaging Oligonucleotides as Anticancer Agents: From the Benchside to the Clinic and Beyond
Current Pharmaceutical Design Adipose Stem Cells and Skin Repair
Current Stem Cell Research & Therapy Reversion of Multidrug Resistance in Tumor By Biocompatible Nanomaterials
Mini-Reviews in Medicinal Chemistry Anti-Cancer and Radio-Sensitizing Effects of Curcumin in Nasopharyngeal Carcinoma
Current Pharmaceutical Design The Role of E-Cadherin Down-Regulation in Oral Cancer: CDH1 Gene Expression and Epigenetic Blockage
Current Cancer Drug Targets Recent Advances of Small Molecule Focal Adhesion Kinase (FAK) Inhibitors as Promising Anticancer Therapeutics
Current Medicinal Chemistry Bortezomib as an Antitumor Agent
Current Pharmaceutical Biotechnology